About Lisa Nachtigall, MD
Dr. Lisa Nachtigall is the Director of the Neuroendocrine Clinical Center at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. In addition, she is the director of MGH International Education Programs for the MGH Endocrine Division, and of the MGH/Harvard Medical School advanced clerkship in Clinical Neuroendocrinology. Her primary clinical focus is in pituitary disorders. She has extensive clinical experience in all aspect of pituitary care, particularly acromegaly, and has published clinical research papers in this area. She has received awards for teaching and clinical investigation.
Clinical Interests:
- Acromegaly
- Bone disorders related to neuroendocrine dysfunction
- Hirsuitism
- Hyperandrogenism
- Hyperprolactinemia
- Hypopituitarism
- Pituitary disease
- Pituitary tumors
- Reproductive Dysfunction
Treats:
- Adult
Locations
Mass General Endocrinology: Neuroendocrine & Pituitary Tumor Clinical Center
100 Blossom Street
Cox Building
Suite 140
Boston, MA 02114
Phone: 617-726-7948
Medical Education
- MD, New York University School of Medicine
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Endocrinology, Diabetes and Metabolism, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
My study of how 100 patients with acromegaly came to diagnosis targeted education on this rare disease to professionals who most likely encounter it. I investigated a long acting somatostatin analog with a novel delivery system. I have contributed to several reviews on acromegaly and hyperprolactinemia and edited chapters on these topics. I have created an acromegaly database, including longitudinal data in over 350 patients, which will improve clinical practice strategies and serve as a resource for clinical investigation and as a model for database construction. I received an investigator initiated award to study long term treatment of acromegaly with somatostatin analogs.
Publications
-
Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.
Miller KK, Wexler T, Fazeli P, Gunnell L, Graham GJ, Beauregard C, Hemphill L, Nachtigall L, Loeffler J, Swearingen B, Biller BM, Klibanski A. J Clin Endocrinol Metab. 2010 Feb;95(2):567-77. Epub 2010 Jan 8.
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-na??ve patients with acromegaly.
Salvatori R, Nachtigall LB, Cook DM, Bonert V, Molitch ME, Blethen S, Chang S; SALSA Study Group. Pituitary. 2010 Jun;13(2):115-22.